{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T19:40:44Z","timestamp":1777578044243,"version":"3.51.4"},"reference-count":24,"publisher":"Elsevier BV","issue":"24","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T00:00:00Z","timestamp":1615334400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.vaccine.2021.02.065","type":"journal-article","created":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T19:06:20Z","timestamp":1620155180000},"page":"3296-3303","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Post-licensure observational safety study after meningococcal B vaccine 4CMenB (Bexsero) vaccination within the routine UK immunisation program"],"prefix":"10.1016","volume":"39","author":[{"given":"Gillian C.","family":"Hall","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Douglas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul T.","family":"Heath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1641-8714","authenticated-orcid":false,"given":"Prab","family":"Prabhakar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Rosillon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6815-790X","authenticated-orcid":false,"given":"Javeed","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Abbing-Karahagopian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2021.02.065_b0005","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S1474-4422(12)70180-1","article-title":"Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study","volume":"11","author":"Viner","year":"2012","journal-title":"The Lancet Neurology"},{"key":"10.1016\/j.vaccine.2021.02.065_b0010","unstructured":"National Health Service. Routine childhood immunisations from summer; 2015, https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/500213\/9406_PHE_2016_Routine_Childhood_Immunisation_Schedule_A4_04.pdf."},{"key":"10.1016\/j.vaccine.2021.02.065_b0015","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(12)61961-8","article-title":"Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials","volume":"381","author":"Vesikari","year":"2013","journal-title":"The Lancet"},{"key":"10.1016\/j.vaccine.2021.02.065_b0020","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1473-3099(18)30048-3","article-title":"Immunogenicity and safety of the multicomponent meningococcal B vaccine (4CMenB) in children and adolescents: a systematic review and meta-analysis","volume":"18","author":"Flacco","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2021.02.065_b0025","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1586\/14760584.2013.814862","article-title":"A multicomponent serogroup B meningococcal vaccine is licensed for use in Europe: what do we know, and what are we yet to learn?","volume":"12","author":"Martin","year":"2013","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2021.02.065_b0030","series-title":"The READ Codes Version 3","author":"NHS Centre for Coding and Classification","year":"1996"},{"key":"10.1016\/j.vaccine.2021.02.065_b0035","first-page":"251","article-title":"Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates","volume":"19","author":"Blak","year":"2011","journal-title":"Inform Prim Care"},{"key":"10.1016\/j.vaccine.2021.02.065_b0040","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/pds.1688","article-title":"The importance of defining periods of complete mortality reporting for research using automated data from primary care","volume":"18","author":"Maguire","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2021.02.065_b0045","unstructured":"The European Parliament and of the Council of the European Union. Regulation (EU) 2016\/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95\/46\/EC (General Data Protection Regulation), https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/PDF\/?uri=CELEX:32016R0679; 2016 [accessed 11\/06\/2020]."},{"key":"10.1016\/j.vaccine.2021.02.065_b0050","doi-asserted-by":"crossref","first-page":"7364","DOI":"10.1016\/j.vaccine.2015.07.093","article-title":"The incidence of childhood and adolescent seizures in the UK from 1999 to 2011: A retrospective cohort study using the Clinical Practice Research Datalink","volume":"33","author":"Sammon","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.02.065_b0055","doi-asserted-by":"crossref","first-page":"e271","DOI":"10.3399\/bjgp16X684325","article-title":"Kawasaki disease incidence in children and adolescents: an observational study in primary care","volume":"66","author":"Hall","year":"2016","journal-title":"Br J Gen Pract"},{"key":"10.1016\/j.vaccine.2021.02.065_b0060","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1002\/sim.2477","article-title":"Sample sizes for self-controlled case series studies","volume":"25","author":"Musonda","year":"2006","journal-title":"Stat Med"},{"key":"10.1016\/j.vaccine.2021.02.065_b0065","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1002\/sim.2302","article-title":"Tutorial in biostatistics: the self-controlled case series method","volume":"25","author":"Whitaker","year":"2006","journal-title":"Stat Med"},{"key":"10.1016\/j.vaccine.2021.02.065_b0070","unstructured":"SAS. Enterprise Guide Version: 713 HF3 for Windows: Copyright\u00a9 2016 by SAS Institute Inc."},{"key":"10.1016\/j.vaccine.2021.02.065_b0075","doi-asserted-by":"crossref","unstructured":"Sun Y, Christensen J, Hviid A, Li J, Vedsted P, Olsen J, et al. Risk of Febrile Seizures and Epilepsy After Vaccination With Diphtheria, Tetanus, Acellular Pertussis, Inactivated Poliovirus, and Haemophilus Influenzae Type b. JAMA: The Journal of the American Medical Association. 2012;307:823-31. https:\/\/doi.org\/10.1001\/jama.2012.165.","DOI":"10.1001\/jama.2012.165"},{"key":"10.1016\/j.vaccine.2021.02.065_b0080","article-title":"ADVANCE system testing: Can safety studies be conducted using electronic healthcare data? An example using pertussis vaccination","author":"Weibel","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.02.065_b0085","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1080\/21645515.2018.1450123","article-title":"Safety study of live, oral human rotavirus vaccine: a cohort study in United States health insurance plans","volume":"14","author":"Hoffman","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2021.02.065_b0090","doi-asserted-by":"crossref","unstructured":"Miller E, Andrews. Risks of convulsion and aseptic meningitis following measles-mumps-rubella vaccination in the United Kingdom. American Journal of Epidemiology. 2007;165:704. https:\/\/doi.org\/10.1093\/aje\/kwk045.","DOI":"10.1093\/aje\/kwk045"},{"key":"10.1016\/j.vaccine.2021.02.065_b0095","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1002\/pds.4108","article-title":"The incidence of Kawasaki disease after vaccination within the UK pre-school National Immunisation Programme: an observational THIN database study","volume":"25","author":"Hall","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2021.02.065_b0100","doi-asserted-by":"crossref","first-page":"4935","DOI":"10.1016\/j.vaccine.2020.05.089","article-title":"The risk of Kawasaki disease after pneumococcal conjugate & meningococcal B vaccine in England: a self-controlled case-series analysis","volume":"38","author":"Stowe","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.02.065_b0105","doi-asserted-by":"crossref","DOI":"10.1136\/archdischild-2011-301163","article-title":"Anaphylaxis as an adverse event following immunisation in the UK and Ireland","author":"Erlewyn-Lajeunesse","year":"2012","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.vaccine.2021.02.065_b0110","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1542\/peds.112.4.815","article-title":"Risk of anaphylaxis after vaccination of children and adolescents","volume":"112","author":"Bohlke","year":"2003","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2021.02.065_b0115","doi-asserted-by":"crossref","first-page":"5253","DOI":"10.1016\/j.vaccine.2007.03.053","article-title":"Guillain-Barre syndrome after vaccination in United States: a report from the CDC\/FDA Vaccine Adverse Event Reporting System","volume":"25","author":"Souayah","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.02.065_b0120","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1128\/CVI.00307-13","article-title":"Acute disseminated encephalomyelitis following seasonal influenza vaccination in an elderly patient","volume":"20","author":"Machicado","year":"2013","journal-title":"Clin. Vaccine Immunol.: CVI"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21002565?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21002565?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:56:11Z","timestamp":1759402571000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21002565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":24,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S0264410X21002565"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.02.065","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Post-licensure observational safety study after meningococcal B vaccine 4CMenB (Bexsero) vaccination within the routine UK immunisation program","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.02.065","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}